Centennial Heart at Parkridge, HCA Healthcare, 2205 McCallie Avenue, Chattanooga, TN, 37404, USA.
Department of Medicine, Erlanger Heart and Lung Institute/University of Tennessee College of Medicine Chattanooga, Chattanooga, TN, USA.
Curr Cardiol Rep. 2021 Apr 6;23(5):52. doi: 10.1007/s11886-021-01475-6.
Hepatitis C virus (HCV) and atherosclerotic cardiovascular disease (ASCVD) are two diseases that affect millions around the globe. Hepatitis C affects more than 70 million individuals globally. ASCVD is commonly encountered and remains the top cause of death worldwide. A link has been identified between HCV and atherosclerosis.
A review of recent studies which define the association between HCV infection and an increased risk of subclinical ASCVD and experiencing cardiovascular (CV) events. It is now recognized that there is an increased burden of atherosclerosis in individuals infected with HCV that translates into increased cardiovascular events. An increase in the number of diagnosed cases of HCV is expected as screening recommendations for the virus have expanded. Strategies to educate healthcare professionals about this increased CV risk will need to be considered as well as the optimal strategy to lower CV risk in this growing population.
丙型肝炎病毒 (HCV) 和动脉粥样硬化性心血管疾病 (ASCVD) 是两种影响全球数百万人的疾病。全球有超过 7000 万人感染 HCV。ASCVD 是一种常见的疾病,仍然是全球死亡的主要原因。已经确定 HCV 与动脉粥样硬化之间存在关联。
最近的研究综述了 HCV 感染与亚临床 ASCVD 风险增加和心血管 (CV) 事件发生之间的关系。现在已经认识到,感染 HCV 的个体中动脉粥样硬化的负担增加,这转化为心血管事件的增加。随着对该病毒筛查建议的扩大,预计 HCV 诊断病例的数量将会增加。需要考虑向医疗保健专业人员宣传这种增加的 CV 风险的策略,以及在这个不断增长的人群中降低 CV 风险的最佳策略。